Product Description
Mechanisms of Action: alkaline phosphate Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Brazil | Canada | Chile | China | Colombia | Dominican Republic | Egypt | Germany | Hungary | India | Indonesia | Ireland | Italy | Latvia | Lithuania | Malaysia | New Zealand | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovenia | Sri Lanka | Taiwan | Turkey | Ukraine | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|